Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01850147|
Recruitment Status : Unknown
Verified May 2013 by LI Junling, Chinese Academy of Medical Sciences.
Recruitment status was: Recruiting
First Posted : May 9, 2013
Last Update Posted : May 9, 2013
|Condition or disease||Intervention/treatment||Phase|
|Cancer Lung Cancer||Drug: Sunitinib, chemotherapy||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of Efficacy and Safety of Sequential Low-dose Sunitinib With Chemotherapy in Advanced Non-small Cell Lung Cancer After Failure of Conventional Regimen|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||October 2014|
|Estimated Study Completion Date :||December 2014|
Drug: Sunitinib, chemotherapy
sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
- progression-free survival [ Time Frame: up to 2 years ]The primary objective of this study is to evaluate the median progression-free survival of this sequential regimen.
- overall survival [ Time Frame: up to 2 years ]To evaluate the median over-all survival of this regimen
- disease control rate [ Time Frame: up to 6 months ]To evaluate the disease-control rate of this regimen.
- Safety [ Time Frame: up to 2 years ]To evaluate the safety of this regimen including the rate and grade of adverse effects.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01850147
|Contact: Junling Liemail@example.com|
|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||Recruiting|
|Beijing, China, 100021|